Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

from Value in Health at on June 21, 2017 at 06:58AM

Publication date:
Source:Value in Health
Author(s): Isaac Corro Ramos, Matthijs M. Versteegh, Rudolf A. de Boer, Jolanda M.A. Koenders, Gerard C.M. Linssen, Joan G. Meeder, Maureen P.M.H. Rutten-van Mölken